openPR Logo
Press release

Depression Drugs Market Future Outlook and Active Company Profiles during 2018-2026

02-03-2020 11:23 AM CET | Health & Medicine

Press release from: Fact.MR

Depression Drugs Market Future Outlook and Active Company

Thedepression drugs market, valued at over US$ 6.5 billion in 2017, is likely to witness bearishness in the near future, with a new report by Fact.MR estimating revenues to decline at a -2% CAGR. According to the study, although the prevalence rate of depression has gone up in the last decade, preference for cognitive behavior therapy (CBT) and awareness about the potential side effects has led to a decline in demand for depression drugs. The study finds that US continued to be at the forefront in terms of total depression drugs sold in 2018.

According to the World Health Organization (WHO), depression has become one of the common illnesses, affecting over 300 million people across the world. In the United States, approximately 10.3 million adults had experienced at least one major depressive episode that resulted in severe impairment, according to the National Institute of Mental Health (NIMH). High prevalence of such depressive episode was observed among people aged 18-25 (10.9%), female adults (8.5%), and male adults (4.8%). According to the Fact.MR study, although depression continues to be a major health issue, medical community and patients are encouraging a non-drug approach to reduce side effects and dependency. Healthcare providers and patients are focusing on cognitive behavior therapy (CBT) and mindfulness-based approaches to foster a long-term management of depression and other mental health issues.

Popularity of Tech-based Mental Health Apps also contributing to Low Sales

The study finds that demand for depression drugs is also witnessing a decline as end-users have more coping options at their disposal. The huge popularity of mental health apps, such as Headspace, Calm, Moodnotes, Pacifica, and SuperBetter has given patients more control over how they manage depression. Considering the growing body of research supporting the use of meditation and cognitive behavior therapy, the proliferation of tech apps has witnessed a spike in the recent years. The study finds that depression drugs market will continue to be influenced by these evolutions.

You can Request an Example Copy from here - https://www.factmr.com/connectus/sample?flag=S&rep_id=3215

Depression Drugs Market to Remain Concentrated in Developed Nations

North America and Europe are the two largest depression drugs market globally, owing to concentration of leading market players and increase in R&D of these drugs. While there has been a rising burden of mental illness such as bipolar I disorder and schizophrenia in China and India, lack of wide-ranging awareness regarding antidepressant medications (ADMs) is expected to negatively affect the growth of depression drugs market in the Asia Pacific region. Moreover, different therapies of depression are as efficacious as ADM and their effects are more enduring, which may create a hindrance in future expansion of depression drugs market, especially in Asia Pacific and Middle East & Africa.

Depression Drugs Market: Segment-wise Insights

On the basis of drug class, the global depression drugs market has been segmented into SSRIs, atypical antipsychotics, SNRIs, CNS stimulants, and others. Of these, atypical antipsychotics is expected to contribute the largest share in the market. Major depressive disorder has been envisaged to account for the most substantial share in the depression drugs market based on disease type. Other sub-segments include SSRI induced, schizophrenia, and bipolar I disorder. While depression drugs are sold across retail, hospital, and online pharmacies, the retail segment registered the largest share in 2017, and the trend is expected to continue during the 2018-2026 period.

Ask Industry Professional about Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=3215

Global Depression Drugs Market: Competitive Landscape

Some key players operating in the manufacturing of depression drugs are Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson,Sebela Pharmaceutical Inc., GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Allergan USA, Inc., Takeda Pharmaceutical Company Ltd, Novartis AG, Pfizer, Inc., Alkermes Plc, H. Lundbeck, Bristol Myers Squibb Co., and Teva Pharmaceutical Industries Ltd.

Contact Us

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Depression Drugs Market Future Outlook and Active Company Profiles during 2018-2026 here

News-ID: 1916566 • Views: 408

More Releases from Fact.MR

01-21-2021 | Health & Medicine
Fact.MR
Cardiac Ablation Technologies Market
Growing acceptance of catheter ablation as the first line of therapy, along with recent developments introducing robotic catheter navigation systems and 3D electro-anatomical mapping systems creates a highly conducive environment for the growth of the cardiac ablation technologies market. However, an extensive study published by Fact.MR raises concerns regarding technical complexity leading to lack of required operational competency, which leads to fundamental barriers to the adoption of advanced ablation systems. Request
01-21-2021 | Health & Medicine
Fact.MR
Carbapenem-based Antibiotics Market to Exhibit 7% CAGR, with Sales of Tebipenem …
Incidence of bacterial infections with multidrug resistance is increasing rapidly, generating the need for novel, broad-spectrum carbapenem-based antibiotics for the treatment of various bacterial infections. Broad-spectrum carbapenem-based antibiotics such as tebipenem (Spero Therapeutics Inc.) and sulopenem (Iterum Therapeutics Inc.) are at late stage clinical development with expected launch of both in 2020 - 2021. Multidrug resistance to currently marketed carbapenem-based antibiotics is largely prevalent in the world. Also, expiry of
01-21-2021 | Health & Medicine
Fact.MR
Asthma Treatment Market Projected to Witness a Double-Digit CAGR During 2020 to …
Retail pharmacies will drive the highest sales of asthma therapeutics with an estimated value of around US$ 17 Bn by 2027, as rapid expansion of retail pharmacies makes asthma therapeutics more accessible to patients. According to a recent Fact.MR study, hospital pharmacies with large drug inventories would also remain a crucial distribution channel in the asthma treatment market. As patients find it convenient to purchase drugs immediately after diagnosis, hospital
01-21-2021 | Health & Medicine
Fact.MR
Dental Consumables Market to Top US$ 50 Bn by 2030
Dental problems are becoming a cause for concern for people worldwide. This has led to manufacturers investing in research & development to come up with innovative products with changing times. Technological advancements leading to innovative products are expected to drive the global dental consumables market in the future. Request a report sample to gain comprehensive market insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4420 For instance, due to problems created by the COVID 19 pandemic, companies are

All 5 Releases


More Releases for Drugs

Acne Drugs: Global Markets
The global market for acne drugs was valued at REDACTED in 2019. The market is expected to growat a compound annualgrowth rate (CAGR) of REDACTED to reach REDACTED by 2025. Growth of the global market is attributed the increasing numberof cases of acne and skin diseases, unhealthy eating habits and the rising adoption of skin care productsworldwide. To Get Sample Copy of Report Visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=2798596 Increasing prevalence of the acne and
Acne Drugs Market
According to IMARC Group’s latest report, titled “Acne Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025,”. Looking forward, IMARC Group expects the global acne drugs market to continue its moderate growth during the next five years. Acne drugs are medications used to treat a dermatological infection caused by the inflammation in the hair follicles on the skin. It is generally due to hormonal imbalance, oily skin, accumulation of
Global Cardiovascular Drugs Market
Global Cardiovascular Drugs Market – Industry Analysis and Forecast (2018-2026) – by Drug Class, Indications, Distribution Channels, and Region. Global Cardiovascular Drugs Market was valued at US$ 80.5 Bn in 2017 and is expected to reach US$ 98.8 Bn by 2026, at a CAGR of 2.6 % during the forecast period. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data,
Cardiovascular Drugs Market | Insights
Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease. Major problems associated with hypertensive heart disease include angina, hypertrophy, and heart failure. These problems are caused due to high blood pressure in the heart’s arteries and muscles, which causes narrowing of arteries and thickening and enlargement of heart. The global cardiovascular drug market is primarily driven
Immunotherapy Drugs Market
Immunotherapy drugs are used to treat cancer, infection, respiratory and autoimmune disorders. Immunotherapies either stimulate the activities done by specific components of the immune system or counteract the signals that are produced by the cancer cells and suppress the immune responses. The Immunotherapy Drugs Market accounted to USD 107 billion in 2016 growing at a CAGR of 13.2% during the forecast period of 2017 to 2024. The upcoming market report contains
Immunotherapy Drugs Market
Immunotherapy is the management of a disease by enhancing, suppressing, or inducing an immune response. Some immunotherapies are designed to magnify or elicit an immune response. They are known as activation immunotherapies. However, some immunotherapies that suppress or reduce the immune response are known as suppression immunotherapies. Cell-based immunotherapies are useful for some types of cancers. Immune effector cells includingmacrophages, dendritic cells, lymphocytes, cytotoxic T lymphocytes (CTL), natural killer cells